Opendata, web and dolomites


Leveraging Small Demethylase inhibitors for Autism Spectrum Disorder

Total Cost €


EC-Contrib. €






 LSDiASD project word cloud

Explore the words cloud of the LSDiASD project. It provides you a very rough idea of what is the project "LSDiASD" about.

vulnerable    sociability    function    copy    individuals    splitting    spectrum    therapeutic    stereotyped    duplication    symptoms    comprising    chromosome    disability    lesions    traits    causing    caused    few    prerequisites    diseases    discovered    neurodevelopmental    despite    broadly    core    yield    7dup    recapitulating    deficits    convergence    demethylase    hope    efficacy    phenotypes    found    cognitive    treatment    prevalent    vivo    gtf2i    turn       de    dosage    rescues    region    400    intellectual    inhibition    26    clinical    dependent    consistency    rare    underlying    point    industrial    23    facto    wish    autistic    consolidator    proof    convergent    behaviours    chromatin    rescuing    asd    generalizable    behavioural    alterations    represses    worldwide    advancing    7q11    erc    penetrant    syndromes    remarkable    featuring    models    competence    genetic    causative    disorder    symmetrically    points    mouse    language    diseaseavatars    business    neuronal    modifier    syndrome    grounds    28    aggregate    transcription    inhibitor    plan    gene    lysine    paradigmatic    associating    hemideletion    williams    dissect    circuits    cnv    lsd1    opposite    inhibitors    autism    impairment    inroads    genes    variations   

Project "LSDiASD" data sheet

The following table provides information about the project.


Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 145˙250 €
 EC max contribution 145˙250 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2018-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 107˙750.00
2    TTFACTOR SRL IT (MILANO) participant 37˙500.00


 Project objective

Duplication of chromosome region 7q11.23 (7Dup), comprising 26-28 genes, is one of best characterized copy number variations (CNV) causing Autism Spectrum Disorder (ASD), a very prevalent neurodevelopmental condition affecting more than 1% individuals worldwide, and for which no effective treatment is available. Despite the remarkable consistency of core ASD symptoms (impairment in language and sociability along with stereotyped behaviours), over 400 causative genetic lesions have been thus far identified for ASD, splitting it de facto into an aggregate of rare and highly penetrant genetic diseases. In turn, the convergence of symptoms grounds the hope that few paradigmatic syndromes may yield generalizable therapeutic inroads across the autistic spectrum. 7Dup is a case in point since it is symmetrically opposite to Williams Syndrome, a condition caused by 7q11.23 hemideletion and featuring symmetrically opposite phenotypes in language and sociability, thus offering unique opportunities to dissect the dosage-vulnerable circuits that affect language competence and sociability. Specifically, convergent evidence points to transcription factor GTF2I as the key gene underlying the cognitive/behavioural traits of 7Dup. Within my ERC-Consolidator project DISEASEAVATARS we discovered that increased GTF2I dosage represses key genes involved in intellectual disability, autism and neuronal function by associating with lysine demethylase 1 (LSD1), a key chromatin modifier, and found that LSD1 inhibition rescues GTF2I-dependent alterations. Therefore, we now wish to establish in vivo proof of concept for the efficacy of novel LSD1 inhibitors in rescuing cognitive-behavioural deficits in relevant ASD mouse models recapitulating GTF2I CNV, developing an adequate business plan and industrial partnerships as prerequisites for advancing the most effective LSD1 inhibitor towards pre-clinical development for 7Dup and ASD more broadly.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LSDIASD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LSDIASD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  


The Mass Politics of Disintegration

Read More